Skip to main content
SpringerLink
Log in

Plasmaaustausch als Therapieoption bei neurologischen Erkrankungen

Plasma exchange as a therapeutic option in neurological disorders

  • Übersichten
  • Published:
Der Nervenarzt Aims and scope Submit manuscript

Zusammenfassung

Plasmaaustausch ist ein etabliertes therapeutisches Verfahren, das bei zahlreichen neurologischen Erkrankungen breite Anwendung findet. In der vorliegenden Arbeit soll eine Übersicht über die gegenwärtige Rolle des Plasmaaustauschs als Therapieoption bei verschiedenen Erkrankungen des peripheren und zentralen Nervensystems gegeben werden.

Summary

Plasma exchange is a therapeutic procedure commonly used in various neurological disorders. Here we review its current role as a treatment option in diseases of the central and peripheral nervous system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Lehmann HC, Hartung H-P, Hetzel GR et al. (2006) Plasma exchange in neuroimmunological disorders. Part 1 Rationale and treatment of central nervous system disorders. Arch Neurol 63: 930–935

    Article  PubMed  Google Scholar 

  2. Lehmann HC, Hartung H-P, Hetzel GR et al. (2006) Plasma exchange in neuroimmunological disorders. Part 2 Treatment of neuromuscular disorders. Arch Neurol 63: 1066–1071

    Article  PubMed  Google Scholar 

  3. Weinstein R (2000) Therapeutic apheresis in neurological disorders. J Clin Apheresis 15: 74–128

    Article  PubMed  Google Scholar 

  4. Drachman DB (1994) Myasthenia gravis. N Engl J Med 330: 1797–1810

    Article  PubMed  Google Scholar 

  5. Lennon VA, Kryzer TJ, Griesmann GE et al. (1995) Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 332: 1467–1474

    Article  PubMed  Google Scholar 

  6. Berger T, Rubner P, Schautzer F et al. (2003) Antimyelin antibodies as a predictor of clinical definite multiple sclerosis after a first demyelinating event. N Engl J Med 349: 139–145

    Article  PubMed  Google Scholar 

  7. Kaplan AA (1999) A practical guide to therapeutic plasma exchange. In: Kaplan AA (ed) Blackwell Sciences, Malden, pp 5–17

  8. Reeves JH, Butt WW, Shann F et al. (1999) Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. Crit Care Med 27: 2096–2104

    Article  PubMed  Google Scholar 

  9. Hershko AY, Naparstek Y (2005) Removal of pathogenic autoantibodies by immunoadsorption. Ann N Y Acad Sci 1051: 635–646

    Article  PubMed  Google Scholar 

  10. Moldenhauer A, Haas J, Wascher C et al. (2005) Immunoadsorption patients with multiple sclerosis: an open-label pilot study. Eur J Clin Invest 35: 523–530

    Article  PubMed  Google Scholar 

  11. Yeh JH, Chiu HC (2000) Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis. J Neurol 247: 510–513

    Article  PubMed  Google Scholar 

  12. Mokrzycki MH, Kaplan AA (1994) Therapeutic plasma exchange: complications and management. Am J Kidney Dis 23: 817–827

    PubMed  Google Scholar 

  13. Rodnitzky RL, Goeken JA (1982) Complications of plasma exchange in neurological patients. Arch Neurol 39: 350–354

    PubMed  Google Scholar 

  14. Boucher CA, Gans J de, Oers R van et al. (1988) Transmission of HIV and AIDS by plasmapheresis for Guillain-Barre syndrome. Clin Neurol Neurosurg 90: 235–236

    Article  PubMed  Google Scholar 

  15. Hahn AF (1998) Guillain-Barré syndrome. Lancet 352: 635–641

    Article  PubMed  Google Scholar 

  16. Hartung HP, Willison HJ, Kieseier BC (2002) Acute immunoinflammatory neuropathy: update on Guillain-Barré syndrome. Curr Opin Neurol 15: 571–577

    Article  PubMed  Google Scholar 

  17. Yuki N (2001) Infectious origins of, and molecular mimicry in Guillain-Barré and Fisher syndromes. Lancet Infect Dis 1: 29–37

    Article  PubMed  Google Scholar 

  18. Willison HJ, Yuki N (2002) Peripheral neuropathies and anti-glycolipid antibodies. Brain 125: 2591–2625

    Article  PubMed  Google Scholar 

  19. Hadden RD, Karch H, Hartung HP et al. (2001) Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology 56: 758–765

    PubMed  Google Scholar 

  20. Rees JH, Soudain SE, Gregson NA, Hughes RA (1995) Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 333: 1374–1379

    Article  PubMed  Google Scholar 

  21. The Guillain-Barre syndrome Study Group (1985) Plasmapheresis and acute Guillain-Barre syndrome. Neurology 35: 1096–1104

    PubMed  Google Scholar 

  22. The French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome (1987) Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 22: 753–761

    Article  PubMed  Google Scholar 

  23. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome (1997) Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 41: 298–306

    Article  PubMed  Google Scholar 

  24. Sanjay R, Flanagan J, Sodano D et al. (2006) The acute phase reactant, fibrinogen, as a guide to plasma exchange therapy for acute Guillain-Barré syndrome. J Clin Apher 21:105-110

    Article  PubMed  Google Scholar 

  25. Meche FG van der, Schmitz PI (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. The Dutch Guillain-Barré Study Group. N Engl J Med 326: 1123–1129

    PubMed  Google Scholar 

  26. Greenwood RJ, Newsom-Davis J, Hughes RA et al. (1984) Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1: 877–879

    Article  PubMed  Google Scholar 

  27. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group (1997) Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 349: 225–230

    Article  PubMed  Google Scholar 

  28. Haupt WF, Rosenow F, Ven C van der, Birkmann C (2000) Immunoadsorption in Guillain-Barre syndrome and myasthenia gravis. Ther Apher 4: 195–197

    Article  PubMed  Google Scholar 

  29. Okamiya S, Ogino M, Ogino Y et al. (2004) Tryptophan-immobilized column-based immunoadsorption as the choice method for plasmapheresis in Guillain-Barre syndrome. Ther Apher Dial 8: 248–253

    Article  PubMed  Google Scholar 

  30. Willison HJ, Townson K, Veitch J et al. (2004) Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmune neuropathy sera. Brain 127: 680–691

    Article  PubMed  Google Scholar 

  31. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force (1991) Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 41: 617–618

    PubMed  Google Scholar 

  32. Hartung HP, Meche FG van der, Pollard JD (1998) Guillain-Barré syndrome, CIDP and other chronic immune-mediated neuropathies. Curr Opin Neurol 11: 497–513

    Article  PubMed  Google Scholar 

  33. Koller H, Kieseier BC, Jander S, Hartung HP (2005) Chronic inflammatory demyelinating neuropathy. N Engl J Med 352: 1343–1356

    Article  PubMed  Google Scholar 

  34. Koski CL (2002) Therapy of CIDP and related immune-mediated neuropathies. Neurology 59: S22–S27

    PubMed  Google Scholar 

  35. Toyka KV, Gold R (2003) The pathogenesis of CIDP: Rationale for treatment with immunomodulatory agents. Neurology 60: S2–S7

    Article  Google Scholar 

  36. Sutton IJ, Winer JB (2002) Immunosuppression in peripheral neuropathy: rationale and reality. Curr Opin Pharmacol 2: 291–295

    Article  PubMed  Google Scholar 

  37. Dyck PJ, Daube J, O’Brien P et al. (1986) Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 314: 461–465

    PubMed  Google Scholar 

  38. Hahn AF, Bolton CF, Pillay N et al. (1996) Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 119: 1055–1066

    Article  PubMed  Google Scholar 

  39. Dyck PJ, Litchy WJ, Kratz KM et al. (1994) A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36: 838–845

    Article  PubMed  Google Scholar 

  40. Kelly JJ Jr, Kyle RA, O’Brien PC, Dyck PJ (1981) Prevalence of monoclonal protein in peripheral neuropathy. Neurology 31: 1480–1483

    PubMed  Google Scholar 

  41. Joint Task Force of the EFNS and PNS (2006) Guideline on management of paraproteinemic demyelination neuropathies. JPNS 19: 9–19

    Google Scholar 

  42. Steck A, Stalder AK, Renaud S (2006) Anti-myelin-associated glycoprotein neuropathy. Curr Opin Neurol 119: 459–4636

    Google Scholar 

  43. Nobile-Orazio E (2004) IgM paraproteinaemic neuropathies. Curr Opin Neurol 17: 599–605

    Article  PubMed  Google Scholar 

  44. Dyck PJ, Low PA, Windebank AJ et al. (1991) Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 325: 1482–1486

    PubMed  Google Scholar 

  45. Hemmer B, Archelos JJ, Hartung HP (2002) New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 3: 291–301

    Article  PubMed  Google Scholar 

  46. Noseworthy JH, Hartung HP (2006) Multiple Sclerosis and related conditions. In: Noseworthy JH (ed) Neurological Therapeutics, Principles and Practice. 2nd edn. Informa Health Care, Abingdon

  47. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343: 938–952

    Article  PubMed  Google Scholar 

  48. Archelos JJ, Storch MK, Hartung HP (2000) The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol 47: 694–706

    Article  PubMed  Google Scholar 

  49. Khatri BO, McQuillen MP, Harrington GJ et al. (1985) Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology 35: 312–319

    PubMed  Google Scholar 

  50. The Canadian Cooperative Multiple Sclerosis Study Group (1991) The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 337: 441–446

    PubMed  Google Scholar 

  51. Sorensen PS, Wanscher B, Szpirt W et al. (1996) Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study. Neurology 46: 1620–1625

    PubMed  Google Scholar 

  52. Goodin DS, Frohman EM, Garmany GP et al. (2002) Disease modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcomitte of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58: 74–80

    Google Scholar 

  53. Weiner HL, Dau PC, Khatri BO et al. (1989) Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 39: 1143–1149

    PubMed  Google Scholar 

  54. Weinshenker BG, O’Brien PC, Petterson TM et al. (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46: 878–886

    Article  PubMed  Google Scholar 

  55. Keegan M, Konig F, McClelland R et al. (2005) Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366: 579–582

    Article  PubMed  Google Scholar 

  56. Lucchinetti C, Bruck W, Parisi J et al. (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47: 707–717

    Article  PubMed  Google Scholar 

  57. Ruprecht K, Klinker E, Dintelmann T et al. (2004) Plasma exchange for severe optic neuritis. Neurology 63: 1063–1065

    Google Scholar 

  58. Vincent A, Drachman DB (2002) Myasthenia gravis. Adv Neurol 88: 159–188

    PubMed  Google Scholar 

  59. De Baets M, Stassen MH (2002) The role of antibodies in myasthenia gravis. J Neurol Sci 202: 5–11

    Article  PubMed  Google Scholar 

  60. Conti-Fine BM, Navaneetham D, Karachunski PI et al. (1998) T cell recognition of the acetylcholine receptor in myasthenia gravis. Ann N Y Acad Sci 841: 283–308

    Article  PubMed  Google Scholar 

  61. Lindstrom JM (2000) Acetylcholine receptors and myasthenia. Muscle Nerve 23: 453–477

    Article  PubMed  Google Scholar 

  62. Toyka KV, Brachman DB, Pestronk A, Kao I (1975) Myasthenia gravis: passive transfer from man to mouse. Science 190: 397–399

    Article  PubMed  Google Scholar 

  63. Hoedemaekers AC, Breda Vriesman PJ van, De Baets MH (1997) Myasthenia gravis as a prototype autoimmune receptor disease. Immunol Res 16: 341–354

    PubMed  Google Scholar 

  64. Richman DP, Agius MA, Kirvan CA et al. (1998) Antibody effector mechanisms in myasthenia gravis. The complement hypothesis. Ann N Y Acad Sci 841: 450–465

    Article  PubMed  Google Scholar 

  65. Lewis RA, Selwa JF, Lisak RP (1995) Myasthenia gravis: immunological mechanisms and immunotherapy. Ann Neurol (Suppl 1) 37: S51–S62

    MathSciNet  Google Scholar 

  66. Vincent A, Bowen J, Newsom-Davis J, McConville J (2003) Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol 2: 99–106

    Article  PubMed  Google Scholar 

  67. Hoch W, McConville J, Helms S et al. (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7: 365–368

    Article  PubMed  Google Scholar 

  68. Juel VC (2004) Myasthenia gravis: management of myasthenic crisis and perioperative care. Semin Neurol 24: 75–81

    Article  PubMed  Google Scholar 

  69. National Institutes of Health Consensus Development Conference (1988) The use of therapeutic plasmapheresis for neurological disorders. Transfus Med Rev 2: 48–53

    PubMed  Google Scholar 

  70. Gajdos P, Simon N, Rohan-Chabot P de et al. (1983) [Long-term effects of plasma exchange in myasthenia. Results of a randomized study]. Presse Med 12: 939–942

    PubMed  Google Scholar 

  71. Antozzi C, Gemma M, Regi B et al. (1991) A short plasma exchange protocol is effective in severe myasthenia gravis. J Neurol 238: 103–107

    Article  PubMed  Google Scholar 

  72. Chiu HC, Chen WH, Yeh JH (2000) The six year experience of plasmapheresis in patients with myasthenia gravis. Ther Apher 4: 291–295

    Article  PubMed  Google Scholar 

  73. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (1996) Assessment of plasmapheresis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 47: 840–843

    PubMed  Google Scholar 

  74. Gajdos P, Chevret S, Toyka K (2002) Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev: CD002275

    Google Scholar 

  75. Winters JL, Pineda AA (2003) New directions in plasma exchange. Curr Opin Hematol 10: 424–428

    Article  PubMed  Google Scholar 

  76. Gajdos P, Chevret S, Clair B et al. (1997) Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 41: 789–796

    Article  PubMed  Google Scholar 

  77. Sanders DB (1995) Lambert-Eaton myasthenic syndrome: clinical diagnosis, immune-mediated mechanisms, and update on therapies. Ann Neurol (Suppl 1) 37: S63–S73

    Google Scholar 

  78. Lang B, Waterman S, Pinto A et al. (1998) The role of autoantibodies in Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 841: 596–605

    Article  PubMed  Google Scholar 

  79. Newsom-Davis J, Murray N, Wray D et al. (1982) Lambert-Eaton myasthenic syndrome: electrophysiological evidence for a humoral factor. Muscle Nerve 5: S17–S20

    PubMed  Google Scholar 

  80. Newsom-Davis J, Murray NM (1984) Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 34: 480–485

    PubMed  Google Scholar 

  81. Dau PC, Denys EH (1982) Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome. Ann Neurol 11: 570–575

    Article  PubMed  Google Scholar 

  82. Motomura M, Hamasaki S, Nakane S et al. (2000) Apheresis treatment in Lambert-Eaton myasthenic syndrome. Ther Apher 4: 287–290

    Article  PubMed  Google Scholar 

  83. Kornberg AJ, Pestronk A (1995) Chronic motor neuropathies: diagnosis, therapy, and pathogenesis. Ann Neurol (Suppl 1) 37: S43–S50

    Google Scholar 

  84. Silani V, Scarlato G, Valli G, Marconi M (1980) Plasma exchange ineffective in amyotrophic lateral sclerosis. Arch Neurol 37: 511–513

    PubMed  Google Scholar 

  85. Monstad I, Dale I, Petlund CF, Sjaastad O (1979) Plasma exchange in motor neuron disease. A controlled study. J Neurol 221: 59–66

    Article  PubMed  Google Scholar 

  86. Miller FW, Leitman SF, Cronin ME et al. (1992) Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 326: 1380–1384

    PubMed  Google Scholar 

  87. Nobile-Orazio E (2001) Multifocal motor neuropathy. J Neuroimmunol 115: 4–18

    Article  PubMed  Google Scholar 

  88. Olney RK, Lewis RA, Putnam TD, Campellone JV (2003) Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve 27: 117–121

    Article  PubMed  Google Scholar 

  89. Van Asseldonk JT, Franssen H, Van den Berg-Vos RM et al. (2005) Multifocal motor neuropathy. Lancet Neurol 4: 309–319

    Article  PubMed  Google Scholar 

  90. Stangel M, Hartung HP, Marx P, Gold R (1998) Intravenous immunoglobulin treatment of neurological autoimmune diseases. J Neurol Sci 153: 203–214

    Article  PubMed  Google Scholar 

  91. Carpo M, Cappellari A, Mora G et al. (1998) Deterioration of multifocal neuropathy after plasma exchange. Neurology 50: 1480–1482

    PubMed  Google Scholar 

  92. Specht S, Claus D, Zieschang M (2000) Plasmapheresis in multifocal motor neuropathy: a case report. J Neurol Neurosurg Psychiatry 68: 533–535

    Article  PubMed  Google Scholar 

  93. Zhou D, Srivastave R, Nessler S et al. (2006) Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. PNAJ

  94. Townson K, Boffey J, Nicholl D et al. (2007) Solid phase immunoadsorbtion for therapeutic and analytical studies on neuropathy associated with GM antibodies. Glycobiology (in press)

  95. Zettl UK, Hartung HP, Pahnke A et al. (2006) Lesion pathology predicts response to plasma exchange in secondary progressive MS. Neurology 67: 1515–1516

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Neurologische Klinik, Heinrich-Heine-Universität, Moorenstraße 5, 40225, Düsseldorf, Deutschland

    H. C. Lehmann,  Hans-Peter Hartung & B. C. Kieseier

  2. Klinik für Nephrologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland

    G. R. Hetzel

Authors
  1. H. C. Lehmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hans-Peter Hartung
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. R. Hetzel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. C. Kieseier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans-Peter Hartung.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lehmann, H., Hartung, HP., Hetzel, G. et al. Plasmaaustausch als Therapieoption bei neurologischen Erkrankungen. Nervenarzt 78, 166–176 (2007). https://doi.org/10.1007/s00115-006-2229-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00115-006-2229-1

Schlüsselwörter

Keywords

Search

Navigation